Telomir Pharmaceuticals’ (NASDAQ:TELO – Get Free Report) lock-up period is set to expire on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its initial public offering on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Telomir Pharmaceuticals Trading Up 2.4 %
Shares of NASDAQ:TELO opened at $3.42 on Tuesday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a fifty day moving average of $4.69.
Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Telomir Pharmaceuticals
Telomir Pharmaceuticals Company Profile
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
See Also
- Five stocks we like better than Telomir Pharmaceuticals
- What is Short Interest? How to Use It
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- Want to Profit on the Downtrend? Downtrends, Explained.
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- Retail Stocks Investing, Explained
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.